Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus

Molecular Therapy

Volumn 21, Issue 4, 2013, Pages 842-848

  Moussavi, Maryam ^a   Tearle, Howard ^a   Fazli, Ladan ^a   Bell, John C ^b   Jia, William ^a   Rennie, Paul S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; LUCIFERASE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DRUG ADMINISTRATION; IMMUNOHISTOCHEMISTRY; INTRAPROSTATIC INJECTION; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; POLYMERASE CHAIN REACTION; PROSTATE ADENOCARCINOMA; VESICULAR STOMATITIS VIRUS; VIRUS STRAIN;

MUS; VESICULAR STOMATITIS VIRUS;

EID: 84878538123     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.285     Document Type: Article

References (48)

1. Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J, Murray, T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Andrieu, C, Taieb, D, Baylot, V, Ettinger, S, Soubeyran, P, De-Thonel, A et al. (2010). Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 29: 1883-1896.
3. Chang, G, Xu, S, Watanabe, M, Jayakar, HR, Whitt, MA and Gingrich, JR (2010). Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. J Urol 183: 1611-1618.
4. Fusi, A, Procopio, G, Della Torre, S, Ricotta, R, Bianchini, G, Salvioni, R et al. (2004). Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 90: 535-546.
5. Petrylak, DP (2005). Future directions in the treatment of androgen-independent prostate cancer. Urology 65(suppl. 6): 8-12.
6. Huang, B, Sikorski, R, Kirn, DH and Thorne, SH (2011). Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther 18: 164-172.
7. Lun, X, Chan, J, Zhou, H, Sun, B, Kelly, JJ, Stechishin, OO et al. (2010). Effcacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther 18: 1927-1936.
8. Touchefeu, Y, Harrington, KJ, Galmiche, JP and Vassaux, G (2010). Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology. Aliment Pharmacol Ther 32: 953-968.
9. Alajez, NM, Mocanu, JD, Shi, W, Chia, MC, Breitbach, CJ, Hui, AB et al. (2008). Effcacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res 14: 4891-4897.
10. Ribacka, C and Hemminki, A (2008). Virotherapy as an approach against cancer stem cells. Curr Gene Ther 8: 88-96.
11. Zhang, W, Cai, R, Luo, J, Wang, Y, Cui, Q, Wei, X et al. (2007). The oncolytic adenovirus targeting to TERT and RB pathway induced specifc and potent anti-tumor effcacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther 6: 1726-1732.
12. Nagano, K, Masters, JR, Akpan, A, Yang, A, Corless, S, Wood, C et al. (2004). Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 23: 1693-1703.
13. Shou, J, Soriano, R, Hayward, SW, Cunha, GR, Williams, PM and Gao, WQ (2002). Expression profling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 99: 2830-2835.
14. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specifc defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
15. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
16. Moussavi, M, Fazli, L, Tearle, H, Guo, Y, Cox, M, Bell, J et al. (2010). Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res 70: 1367-1376.
17. Winter, SF, Cooper, AB and Greenberg, NM (2003). Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 6: 204-211.
18. Gingrich, JR, Barrios, RJ, Morton, RA, Boyce, BF, DeMayo, FJ, Finegold, MJ et al. (1996). Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102.
19. Greenberg, NM, DeMayo, FJ, Sheppard, PC, Barrios, R, Lebovitz, R, Finegold, M et al. (1994). The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifcally to the prostate in transgenic mice. Mol Endocrinol 8: 230-239.
20. Foster, BA, Gingrich, JR, Kwon, ED, Madias, C and Greenberg, NM (1997). Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330.
21. Faul, EJ, Lyles, DS and Schnell, MJ (2009). Interferon response and viral evasion by members of the family rhabdoviridae. Viruses 1: 832-851.
22. de Weerd, NA, Samarajiwa, SA and Hertzog, PJ (2007). Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282: 20053-20057.
23. Hiscott, J (2007). Triggering the innate antiviral response through IRF-3 activation. J Biol Chem 282: 15325-15329.
24. Oldak, M, Tolzmann, L, Wnorowski, A, Podgórska, MJ, Silling, S, Lin, R et al. (2011). Differential regulation of human papillomavirus type 8 by interferon regulatory factors 3 and 7. J Virol 85: 178-188.
25. Tailor, P, Tamura, T and Ozato, K (2006). IRF family proteins and type I interferon induction in dendritic cells. Cell Res 16: 134-140.
26. Caffo, O, Fratino, L, Barbieri, R, Perin, A, Martini, T, Sava, T et al. (2011). Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study. Urol Oncol (in the press).
27. Gleave, M, Goldenberg, SL, Bruchovsky, N and Rennie, P (1998). Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1: 289-296.
28. Yap, TA, Zivi, A, Omlin, A and de Bono, JS (2011). The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8: 597-610.
29. Chen, FL, Armstrong, AJ and George, DJ (2008). Cell signaling modifers in prostate cancer. Cancer J 14: 40-45.
30. Damber, JE and Aus, G (2008). Prostate cancer. Lancet 371: 1710-1721.
31. Shen, MM and Abate-Shen, C (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24: 1967-2000.
32. Freytag, SO, Khil, M, Stricker, H, Peabody, J, Menon, M, DePeralta-Venturina, M et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976.
33. Freytag, SO, Movsas, B, Aref, I, Stricker, H, Peabody, J, Pegg, J et al. (2007). Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15: 1016-1023.
34. Freytag, SO, Stricker, H, Pegg, J, Paielli, D, Pradhan, DG, Peabody, J et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res 63: 7497-7506.
35. Ottolino-Perry, K, Diallo, JS, Lichty, BD, Bell, JC and McCart, JA (2010). Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18: 251-263.
36. Nguyên, TL, Abdelbary, H, Arguello, M, Breitbach, C, Leveille, S, Diallo, JS et al. (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 105: 14981-14986.
37. Ahmed, M, Cramer, SD and Lyles, DS (2004). Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330: 34-49.
38. Carey, BL, Ahmed, M, Puckett, S and Lyles, DS (2008). Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol 82: 12104-12115.
39. Lun, X, Senger, DL, Alain, T, Oprea, A, Parato, K, Stojdl, D et al. (2006). Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 98: 1546-1557.
40. Muik, A, Dold, C, Geiß, Y, Volk, A, Werbizki, M, Dietrich, U et al. (2012). Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med 90: 959-970.
41. Kaplan-Lefko, PJ, Chen, TM, Ittmann, MM, Barrios, RJ, Ayala, GE, Huss, WJ et al. (2003). Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237.
42. Hadaschik, BA, Zhang, K, So, AI, Fazli, L, Jia, W, Bell, JC et al. (2008). Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res 68: 4506-4510.
43. Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted infammation during oncolytic virus therapy severely compromises tumor blood fow. Mol Ther 15: 1686-1693.
44. Oliere, S, Arguello, M, Mesplede, T, Tumilasci, V, Nakhaei, P, Stojdl, D et al. (2008). Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 82: 5735-5749.
45. Tumilasci, VF, Olière, S, Nguyên, TL, Shamy, A, Bell, J and Hiscott, J (2008). Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 82: 8487-8499.
46. Margiotti, K, Wafa, LA, Cheng, H, Novelli, G, Nelson, CC and Rennie, PS (2007). Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Mol Cancer 6: 38.
47. Honda, K, Yanai, H, Negishi, H, Asagiri, M, Sato, M, Mizutani, T et al. (2005). IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
48. Moussavi, M, Assi, K, Gómez-Muñoz, A and Salh, B (2006). Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 27: 1636-1644.